Immunology Sourcebook_CS indd

Size: px

Start display at page:

Download "Immunology Sourcebook_CS indd"

ぜんままるこ
5 years ago
Views:

2 in vivo in vivo in vitro 1 1 2

3 1. GIBCO Dynabeads T T PBL Treg T CD4 HIV OpTmizer w/ 2 AIM V StemPro -34 Macrophage SFM 1 2 CD3 CD D 11344D MHCD31 and CD24 CD3 CD D 11344D MHCD31 and CD24 CD4 CD D 11346D MHCD41 and MHCD254 CD3 CD D 11346D MHCD31 and Dynabeads FlowComp Dynabeads Untouched SYTOX Red S34859 SYTOX Red S34859 SYTOX Red S34859 SYTOX Red MHCD44 S34859 IL-2, IL-7, IL-15 IL-2, IL-7, IL-15 IL-2 IL-2, IL-7, IL-15 TIL CD3 CD45RO 11365D MHCD31 SYTOX IL-2, IL-7, IL-15 Red S34859 T CD3 CD2 1161D IL-2, IL-7, IL-15 T CD3 CD4 IL-2, IL-7, IL-15 CD45RA CD8 T CD3 IL-2 CD3 NK T CD3 CD D 11344D MHCD31 and CD24 NK CD3 (negative) SYTOX Red S34859 IL-2 CD D 11349D IL-2 CD8 CD83 CD86 HLA-DR 1161D 1138D 1147 MHCD834 and MHLDR1 CD34 + CD34 CD D CD and CD1174 = CD11b CD D 1135D CD11b1 and MHCD144 SYTOX Red S34859 SYTOX Red S34859 SYTOX Red S34859 IL-4, GM-CrF, TNF-, IFN- M-CSF,, IL-1, IL-6, IL-11, IL-12 SCF M-CSF, IL3, IL-4, IL-1, IL-13 IFN-, TGF, TNF-, 3

4 Myeloid stem cell CD33 CD34 CD68 CD117 IL-3 IL-3 IL-11 EPO IL-24 Self renewal CD41 CD42b CD61 CD13 Megakaryocyte IL-6 EPO Platelets Erythroblast EPO IL-3 EPO CD36 CD235a E-Cadherin CD13 CD15 CD33 CD116 CD123 IL-3 IL-3 CFU-G (myeloblast) G-CSF IL-5 Basophil Eosinophil Neutrophil IL-4 Mast cell CD13 CD33 CD68 CD117 IL-6 CFU-M (monoblast) CD11c CD13 CD15 CD33 CD115 CD116 CD123 Monocyte Erythrocyte IL-9 CD9 CD23 CD31 CD32 CD41 CD42B CD61 CD62P CD63 CD69 CD12 CD35 CD44 CD55 CD59 CD235a CD11a CD33 CD9 CD23 CD33 CD35 CD5 CD69 CD1 CD15 CD16 CD35 CD62L CD95 Lactoferrin TLR2 Myeloid dendritic cell IL-4 M-CSF Macrophage CD11a CD13 CD14 CD32 CD33 CD62L CD63 CD64 CD68 CD95 TLR2 CSFR1 Platelets CD1a CD11b CD11c CD68 CD8 CD83 CD11a CD11c CD14 CD16 CD26 CD32 CD36 CD38 CD45b CD63 CD64 CD68 CD8 HLA Class II (DR/DP) CD23 (activated) CD69 (activated) CD15 (activated) Figure 1. Invitrogen tools help you pave the way to immunology discoveries. 4

5 Hematopoietic stem cell CD34 CD45 CD9 CD15 CD117 IL-3 SCF IL-3 Lymphoid stem cell CD1 CD34 CD38 CD117 Self renewal IFN-γ Self renewal CD1 CD24 CD34 CD79a CD79b CD1 CD19 CD2 CD24 CD79a CD79b Pax5 B cell progenitor Intermediate B cell IL-3 IL-4 IL-6 IL-7 CD2 CD3 CD4 CD5 CD7 CD8 CD38 T cell progenitor IL-2 IL-4 IL-7 CD2 ThO Cells CD3 CD4 CD5 CD6 CD7 CD8 CD26 CD38 CD45RO IL-2 IFN-γ Tc cell CD8 CD28 CD95L Granzyme TCR IL-2 IL-15 NK cell CD2 CD7 CD8 CD11b CD16a CD26 CD56 CD57 CD69 CD94 IL-2RB NKG2D CD19 CD2 CD23 CD24 CD79a CD79b Pax5 Mature B cell Th1 IL-27 IFN-α IL-12 IL-23 IL-4 IL-15 IL-25 Th2 TGF-β IL-23 IL-6 Th17 NKT Treg Activated B cell CD25 CD3 CD8 CD86 CD126 IL-6 CD3 CD4 CD26 CXCR3 CCR5 IL-12R IL-18R TCR CD3 CD4 CD3 CCR4 CCR8 CXCR4 TCR CD3 CD4 TCR IL-12R IL-23R CD28 NK1.1 CD1d CD16 CD56 Granzyme TCRα/β CD3 CD4 CD25 FoxP3 TCR Plasma cell CD28 CD38 CD138 IL-6R 5

Dynabeads Dynabeads DynaMag 2 1 3 Dynabeads Dynabeads A B 2 DynaMag -15 A DynaMag -5 B Negative

isolation kits Incubate Dynabeads with the cells in your starting sample Use magnet to separate

6 Dynabeads Dynabeads DynaMag Dynabeads Dynabeads A B 2 DynaMag -15 A DynaMag -5 B Negative isolation Untouched cells Untouched products negative isolation kits FlowComp products positive isolation kits Incubate Dynabeads with the cells in your starting sample Use magnet to separate bead-bound cells Positive isolation Transfer supernatant to a new tube Release cells Bead-free cells 3 Dynabeads 6

Count A 1, 75 5 P2 25 1 2 1 3 1 4 1 5 CD4 FITC-A 7 B 6 5 4 3 2

in vivo Dynabeads 3 4A FlowComp DETACHa-BEAD T Dynabeads 3 4B

7 Count A 1, 75 5 P CD4 FITC-A 7 B CD4 4 Dynabeads Dynabeads FlowComp Human CD4 CD4 T A Dynabeads Untouched Human CD4 T Cells CD4 T B Count Dynabeads 99 Dynabeads CD3/TCR CD28 APC in vivo 5 T APC 14 3, in vivo Dynabeads 3 4A FlowComp DETACHa-BEAD T Dynabeads 3 4B 5 T Dynabeads T in vivo T APC APC CD3 CD28 2 APC 7

8 Ordering information Methodology Human cells Dynabeads Human DC Enrichment Kit Negative selection (only enrichment) 1 kit 113-8D Dynabeads Untouched Human NK Cells Negative selection 1 kit D Dynabeads Untouched Human Monocytes Negative selection 1 kit 113-5D Dynal CD34 Progenitor Cell Selection System Positive isolation with removal of beads and antibody (DETACHaBEAD ) 5 ml 113-1D Dynabeads Biotin Binder Depletion/negative selection 5 ml Dynabeads FlowComp Flexi Positive isolation with removal of beads + antibody-conjugation kit 1 kit 11-61D Dynabeads Untouched Human B Cells Negative isolation 1 kit D Dynabeads Untouched Human T Cells Negative isolation 2 x 5 ml D Dynabeads CD2 Pan T Depletion 5 ml D Dynabeads CD3 Depletion 5 ml D Dynabeads FlowComp Human CD3 Positive isolation 3 ml D Dynabeads CD25 Depletion 5 ml D Dynabeads FlowComp Human CD4 Positive isolation 3 ml D Dynal CD4 Positive Isolation Kit Positive isolation 5 ml D Dynabeads Untouched Human CD4 T Cells Negative isolation 2 x 5 ml D Dynabeads CD4 Depletion 5 ml D Dynal T4 Quant Positive isolation 2 ml D Dynabeads Regulatory CD4 + CD25 + T Cell Kit Positive isolation 2 x 5 ml D Dynabeads FlowComp Human CD8 Positive isolation 3 ml D Dynal CD8 Positive Isolation Kit Positive isolation 5 ml D Dynabeads Untouched Human CD8 T Cells Negative isolation 2 x 5 ml D Dynabeads CD8 Depletion 5 ml D Dynabeads CD3/CD28 Human T-Activator T cell expansion.4 ml D Dynabeads CD3/CD28 Human T-Activator T cell expansion 2 ml D Dynabeads CD3/CD28 Human T-Activator T cell expansion 1 ml D Dynabeads Human Treg Expander Treg cell expansion 2 ml D Dynabeads CD3/CD28 Preclinical T cell expansion 1 ml D Dynabeads ClinExVivo CD3/CD28 (formerly Xcyte Dynabeads ) Clinical-grade T cell expansion 1 ml 42-3D Mouse T cells Dynal Mouse T Cell Negative Isolation Kit Negative isolation 2 x 1 ml D Dynabeads Mouse Pan T (Thy1.2) Depletion 5 ml D Dynabeads FlowComp Mouse Pan T (CD9.2) Positive isolation 3 ml D Dynabeads FlowComp Mouse CD4 Positive isolation 3 ml D Dynal Mouse CD4 Negative Isolation Kit Negative isolation 2 x 1 ml D Dynabeads Mouse CD4 (L3T4) Depletion 5 ml D Dynabeads FlowComp Mouse CD4 + CD25 + Treg Cells Positive isolation 2 x 1 ml D Dynabeads FlowComp Mouse CD8 Positive isolation 3 ml D Dynal Mouse CD8 Negative Isolation Kit Negative isolation 2 x 1 ml D Dynabeads Mouse CD8 (Lyt 2) Depletion 5 ml D Dynabeads Mouse CD3/CD28 Mouse T-Activator T cell expansion.4 ml D Dynabeads Mouse CD3/CD28 Mouse T-Activator T cell expansion 2 ml D Dynabeads Mouse CD3/CD28 Mouse T-Activator T cell expansion 1 ml D Magnets DynaMag -15 Magnet Holds 4 standard 15 ml tubes or 4 x 5 ml tubes Magnetic separation 1 unit 123-1D DynaMag -5 Magnet Holds 2 x 5 ml tubes (5 5 ml) Magnetic separation 1 unit 123-2D 8

9 GIBCO OpTmizer T Cell Expansion SFM GMP T OpTmizer SFM T OpTmizer in vitro T T 5 1 OpTmizer OpTmizer 2 OpTmizer SFM Wave Bioreactor 7 OpTmizer 8 Viable cell density (xt 1 6 cells/ml) Day 7Day 7 Day ⁶ 5 cell/ml Lonza X-VIVO L Stemline S + 5% 5 serum Therapeutics, Inc. OpTmizer OpTmizer + 2% serum 2 7 Wave Bioreactor T PBMC ClinExVivo CD3/CD28 T CD3 T 3 1 T IL Wave Bioreactor CD3 CD4 CD8 CD25 CD154 IFN- T cell viability (%) T A Kohjin 551 Viability Kohjin 561 Density Stemline S Therapeutics, Inc. Lonza X-VIVO Cellgro C OpTmizer 6 TT Dynabeads ClinExVivo CD3/CD /ml T cell/ml Vi-CELL L T cell density ( 1 6 cells/ml) Concentration (pg/ml) pg/ml A 2 8, 7, 6, 5, 4, 3, 2, 1, IFN-γ Kohjin A % serum Stemline S Therapeutics, 2 Inc. + 2% serum Lonza X-VIVO L + 5% 5 serum Cellgro C + 5% 5 serum OpTmizer OpTmizer + 2% 2 serum 8 T T Dynabeads ClinExVivo CD3/ CD /ml T cell/ml

10 OpTmizer OpTmizer Ordering information OpTmizer T Cell Expansion SFM Kit (Bottle) 1 L A14851 OpTmizer T Cell Expansion SFM Kit (Bottle) 5 ml 822SA OpTmizer T Cell Expansion SFM Kit (Bag) 1 L 822SC OpTmizer T Cell Expansion SFM Kit (Bag) 5 L 822SD OpTmizer T Cell Expansion SFM GIBCO AIM V AIM V T cgmp AIM V FDA 51(K) T Relative lysis (%) AIM V Medium 2 RPMI 164 with 2% RPMI human 164serum 2:1 4:1 8:1 Effector target 16:1 AIM V ex vivo 2 IL-2 LAK AIM V AIM V T RMPI 164 LAK 9 AIM V T AIM V LAK 9 AIM V LAK 1, unit/ml IL-2 2 ABRMPI 164 PBL 1 1 cell/ml 6 unit/ml IL-2 AIM V PBL 2 1 cell/ml Daudi 2 3 AIM V 1

11 References 1. Dietze B et al. (28) An improved method to generate equine dendritic cells from peripheral blood mononuclear cells: divergent maturation programs by IL-4 and LPS. Immunobiology 213: Meehan KR et al. (28) Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy 1: Ye Z et al. (26) Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity. Cancer Biother Radiopharm 21: Choi BH et al. (26) Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy. J Clin Apher 21: Imataki O et al. (26) Efficient ex vivo expansion of alpha24+ NKT cells derived from G-CSF-mobilized blood cells. J Immunother 29: Peng JC et al. (25) Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother 28: Trickett AE et al. (22) Ex vivo expansion of functional T lymphocytes from HIVinfected individuals. J Immunol Methods 262: Carlens S et al. (2) Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution. Exp Hematol 28: Kambe N et al. (2) An improved procedure for the development of human mast cells from dispersed fetal liver cells in serum-free culture medium. J Immunol Methods 24: Gerin PA et al. (1999) Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18. Biotechnol Prog 15: Slunt JB et al. (1997) Human T-cell responses to Trichophyton tonsurans: inhibition using the serum free medium Aim V. Clin Exp Allergy 27: Kreuzfelder E (1996) Assessment of peripheral blood mononuclear cell proliferation by [2-3H]adenine uptake in the woodchuck model. Clin Immunol Immunopathol 78: Causey AL (1994) A serum-free medium for human primary T lymphocyte culture. J Immunol Methods 175: Freedman RS et al. (1994) Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 167: Nomura K et al. (1993) [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation.] Nippon Hinyokika Gakkai Zasshi 84: Japanese. 16. Kaldjian EP et al. (1992) Enhancement of lymphocyte proliferation assays by use of serum-free medium. J Immunol Methods 147: Hayakawa K et al. (1991) Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunother McVicar DW et al. (1991) A comparison of serum-free media for the support of in vitro mitogen-induced blastogenic expansion of cytolytic lymphocytes. Cytotechnology 6: Burg S et al. (1991) [Effect of different media on long-term cultivation of human synovial macrophages.] Z Rheumatol 5: German. 2. Helinski EH et al. (1988) Long-term cultivation of functional human macrophages in Teflon dishes with serum-free media. J Leukoc Biol 44: Robyn S et al. (27) RA8, A human anti-cd25 antibody against human Treg cells. Hybridoma 26: Chena X et al. (26) Induction of primary anti-hiv CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentiviral vectors. Cell Immunol 243: Grant R et al. (28) CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells. J Biol Chem 283: Hagihara M et al. (23) Increased frequency of CD3/8/56-positive umbilical cord blood T lymphocytes after allo-priming in vitro. Ann Hematol 82: Wang Z et al. (26) Application of serum-free culture medium for preparation of A-NK cells. Cell Mol Immunol 3: Morecki S et al. (1991) Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells. Cancer Immunol Immunother 32: Johansen P et al. (23) CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells. Eur J Immunol 34: Ordering information Therapeutic grade AIM V Medium, liquid (bottle) 1 L 87112DK AIM V Medium, liquid (bag) 1 L 87112BK Research grade AIM V Medium, liquid 5 ml AIM V Medium, liquid, contains AlbuMAX (BSA) substituted for HSA 5 ml AIM V Medium, liquid 1 L

GIBCO Macrophage-SFM GIBCO Macrophage-SFM GIBCO Macrophage-SFM 1. E.U.

Macrophage- SFM MAC-SFM 1 6 MTT 3- [4,5- -2- ]-2,5-6 12 GIBCO Macrophage-SFM FITC

12 GIBCO Macrophage-SFM GIBCO Macrophage-SFM GIBCO Macrophage-SFM 1. E.U./ml GIBCO Macrophage-SFM 1 11 GIBCO Macrophage-SFM Day 1 3Day 3 6Day 6 OD 595 nm RPMI-164+1% 5 U/mL MAC-SFM 5 U/mL RPMI-164+1% U/mL MAC-SFM U/mL 1 1 FBS RPMI 164 Macrophage- SFM MAC-SFM 1 6 MTT 3- [4, ]-2, GIBCO Macrophage-SFM FITC PBMC Macrophage-SFM PBMC 1 FITC 37 3 PBS Macrophage- SFM 11 Macrophage-SFM rh 1U/ml 45GIBCO Macrophage-SFM 13 GIBCO Macrophage-SFM Macrophage-SFM PBMC 1 2 Ca /Mg D-PBS PBMC 12

13 FBS RPMI GIBCO Macrophage-SFM 13 GIBCO Macrophage-SFM References McNally AK et al. (22) β1 and β2 integrins mediate adhesion during macrophage fusion and multinucleated foreign body giant cell formation. Am J Pathol 16: Zang X et al. (22) Homologues of human macrophage migration inhibitory factor from a parasitic nematode. J Biol Chem 277: Doxey D et al. (1998) Diabetes-induced impairment of macrophage cytokine release in a rat model: potential role of serum lipids. Life Sciences 63: Hasty DL et al. (26) Monocyte and macrophage activation by lipoteichoic acid is independent of alanine and is potentiated by hemoglobin. J Immunol 176: Makkonen J et al. (27) Increased expression of the macrophage markers and of 11β-HSD-1 in subcutaneous adipose tissue, but not in cultured monocytederived macrophages, is associated with liver fat in human obesity. Intl J Obesity 31: Ordering information Macrophage-SFM, (1X), Liquid (Bottle) 5 ml StemPro -34 SFM HSC 1 HSC StemPro -34 SFM SFM StemPro -34 SFM cgmp StemPro -34 SFM HSC 13

14 StemPro -34 SFM HSC CD34 HSC 14 StemPro -34 SFM 2 FBS IMDM StemPro -34 SFM 43 2 FBS IMDM 72 CD34 15 StemPro -34 SFM CD FBS IMDM CD StemPro -34 SFM HSC StemPro -34 SFM StemPro -34 SFM StemPro Nutrient Supplement References Sandstrom CE et al. (1996) Comparison of whole serum-deprived media for ex vivo expansion of hematopoietic progenitor cells from cord blood and mobilized peripheral blood mononuclear cells. J Hematother 5: Carotta S (24) Directed differentiation and mass cultivation of pure erythroid progenitors from mouse embryonic stem cells. Blood 14: Kouskoff V (25) Sequential development of hematopoietic and cardiac mesoderm during embryonic stem cell differentiation. Proc Natl Acad Sci U S A 12: Ando K et al. (26) Direct evidence for ex vivo expansion of human hematopoietic stem cells. Blood 17: Kanatsu-Shinohara M et al. (23) Long-term proliferation in culture and germline transmission of mouse male germline stem cells. Biol Reprod 69: Rookmaaker MB et al. (25) CD34+ cells home, proliferate, and participate in capillary formation, and in combination with CD34- cells enhance tube formation in a 3-dimensional matrix. Arterioscler Thromb Vasc Biol 25: Ordering information StemPro -34 SFM 5 ml ml1 Cells per ml (x 1 5 ) 16 StemPro IMDM + 2% FBS Total cells 12 CD34 + cells ⁴ ⁵ Days in culture Day (n = 1) StemPro -34 SFM CD34 2 FBS IMDM 2 24 CD34 2 1⁴ cell/well SCF 1 ng/ml IL-3 5 ng/ml 25 ng/ ml StemPro -34 SFM 2 FBS IMDM n 1 Cell number (x 1 4 ) StemPro -34 SFM Day 6 8 (n = 18) IMDM medium + 2% FBS Day StemPro -34 SFM CD34 2 FBS IMDM CD ⁴/ml 6 8 StemPro -34 SFM 2 FBS IMDM SCF 1 ng/ml IL-3 5 ng/ml 25 ng/ ml CD FACS 14

15 GIBCO MarrowMAX AmnioMAX PB-MAX MarrowMAX MarrowMAX GCT MarrowMAX MarrowMAX MarrowMAX L- MarrowMAX BrdU BrdU uptake MarrowMAX 4 MarrowMAX 1 1⁵ cell/ml BrdU 45 nm 1 Number of mitotic cells/slide MarrowMAX Basal MarrowMAX GCT-CM GCT-CM A1 GCT-CM GCT-CM B2 16 MarrowMAX MarrowMAX A GCT-CM A B GCT-CM B A B GCT GIBCO MarrowMAX MarrowMAX 24 G 15

16 AmnioMAX 1 AmnioMAX C-1 AmnioMAX AmnioMAX 1 1 medium (Lot 1) 7 MEM-α-2% 2 FBS FBS AmnioMAX medium ⁴ Chang 2 medium (Lot 2) 2 AmnioMAX medium B 5 8 medium (Lot 1) 1 AmnioMAX medium medium (Lot 2) 2 ph AmnioMAX -II 1 AmnioMAX -II Cell number ( 1 4 ) Days in culture 19 AmnioMAX AmnioMAX 2 FBS MEM- 2 AmnioMAX 19 2 AmnioMAX 21 A AmnioMAX Number of obtainable colonies Number of analyzable colonies Chang 1 21 AmnioMAX n 1 AmnioMAX 2 Chang in situ 6 A B A 1 B 6 C Chang medium Chang medium 9 AmnioMAX medium 5 AmnioMAX medium 8 Total cell number ( 1 3 ) Total cell number ( 1 3 ) 1³ Total cell number ( 1 3 ) 1³ 1³ Chang medium AmnioMAX medium 2 AmnioMAX AmnioMAX Chang 1 1 A 1, B 5, C 5 n 6 16

17 AmnioMAX AmnioMAX Chang 22 PB-MAX KaryoMAX PB-MAX KaryoMAX PB-MAX Number of mitotic events per 5, cells AmnioMAX Chang medium AmnioMAX medium 22 AmnioMAX Chang AmnioMAX Chang 6 in situ 5 RPMI PB-MAX KaryoMAX Hanks HBSSPBS KaryoMAX KaryoMAX G Gurr ph L Ordering information MarrowMAX Bone Marrow Medium 1 ml AmnioMAX -II Complete Medium 1 ml AmnioMAX C-1 Complete Medium 1 set AmnioMAX C-1 Basal Medium, liquid 9 ml ml AmnioMAX C-1 Supplement, liquid 15 ml ml PB-MAX Karyotyping Medium 1 ml ml KaryoMAX Colcemid Solution, liquid (1 μg/ml), 1 ml in HBSS KaryoMAX Colcemid Solution, liquid (1 μg/ml), 1 ml in PBS KaryoMAX Giemsa Stain Stock Solution 1 ml Gurr Buffer Tablets (ph 6.8) 5 x 1 L Phytohemagglutinin (M Form) (PHA), liquid 1 ml Potassium chloride solution,.75m 4 x 1 ml

18 1 ELISA Luminex 1 ELISA phosphoelisa Luminex ELISA Luminex NIBSC ELISA Luminex com/immunoassays higher-plex Molecular Probes 1 CD 18

19 GIBCO 23 GIBCO ISO13485 GIBCO OD ED 5 (pg/ml) Invitrogen = Competitor = SCF (pg/ml) 23 MO7e SCF SCF SCF 19

20 1525S

<8DD AA97A3834C B BF8A69838A C8EA E786C7378>

<8DD AA97A3834C B BF8A69838A C8EA E786C7378> ST-01738 ErythroClear Red Blood Cell Depletion Reagent kit 臍帯血 2 ml 用 17,000 13,600 ST-01739 ErythroClear Red Blood Cell Depletion kit 臍帯血 2 ml 用 475,000 380,000 ST-07801 Lymphoprep 250 ml 17,000 13,600